1 primary malignant melanoma of the esophagus has been considered an extremely rare cancer. Among esophageal cancers, primary malignant melanoma accounts for 0.1%-0.2% of cases. 2 We have used CT and positron emission tomography (PET) scans to evaluate metastasis. According to previous re--ports, the rate of metastasis is high when the tumor is first diagnosed.
S ince the first case report was published by Baur in 1906, 1 primary malignant melanoma of the esophagus has been considered an extremely rare cancer. Among esophageal cancers, primary malignant melanoma accounts for 0.1%-0.2% of cases. 2 We have used CT and positron emission tomography (PET) scans to evaluate metastasis. According to previous re--ports, the rate of metastasis is high when the tumor is first diagnosed. 3 Use of PET obviously increases the accuracy of staging. Although primary malignant mela--noma of the esophagus is now better understood, the 5-year survival rate is dismal and treatment remains challenging.
CASE
A 40-year-old woman with 3 months of dysphagia, my--algia over the subscapular region on the left side, and body weight loss (9 kg) was diagnosed with primary malignant melanoma of the esophagus by panendos--copy (PES) with biopsy ( Figure 1 ). After the cancer was confirmed, CT, whole body bone scans and PET scans ( Figure 2 ) were used to establish the clinical stage. An upper gastrointestinal (GI) series was also used to as--sess the axis of the esophagus and the mucosal lesion. The tumor was located about 25 to 30 cm from the inci--sors with a segmental filling defect and mucosal destruc--tion evident in the upper GI series. Chest CT showed wall thickening and a soft-tissue lesion over the middle third of the esophagus, extending for more than 5 cm. Extratumoral extension and lymph node metastasis were considered. PET scans showed bifocal 2-[18F]-Fluoro-2-deoxy-D-glucose (FDG) uptake about the middle third of the esophagus and increased uptake in the right lower-neck region. Tumor markers including carcinoembryonic antigen and squamous cell carcinoma markers were negative.
The patient received subtotal esophagectomy and lymph node dissection after a series of studies. Reconstruction of the esophagus with a gastric tube (substernal route) with cervical esophagogastrostomy was performed after the first step of the operation. A solid fixed lymph node about 3.5×2 cm was noted and dissected. The resected esophageal specimen was 10.5 cm in length and a fungating mass about 4×3.5×2.5 cm was evident in the specimen (Figure 3 ). The final pathology report indicated that the mass was a malig--nant melanoma invading to the submucosal layer and characterized by vesicular hyperchromatic nuclei with prominent eosinophilic nucleoli and frequent mitosis. Immunohistochemical stains for HMB-45 antigen and S-100 protein were positive. The surgical margins were free of tumor invasion, but lymph nodes were noted to contain tumor emboli. We took a biopsy of the cervical lymph node on the basis of the PET findings and, unfor--tunately, a metastasis was found.
DISCUSSION
Primary malignant melanoma of the esophagus is a rare and aggressive tumor with a poor prognosis. Only 15% of all melanomas are encountered in noncutaneous sites, 4 with 0.5% of these arising in the esophagus. 5 Primary malignant melanoma of the esophagus was widely ac-- In 1953, Allen and Spitz developed histological criteria for primary esophageal malignant melanoma, which em--phasized the presence of junctional epithelial changes in the overlying or juxtaposed epithelium near the tumors. 7 No more than 300 cases have been reported world--wide since 1906, most of which were in individual case reports. The symptoms included dysphagia (79.8%), weight loss (37.5%), substernal or epigastric discomfort or pain (33.1%) and melena (7%). Some patients were asymptomatic. The mean duration of symptoms was 3.2 months. It has been shown that esophageal melanocy--tosis is mostly located in the middle and lower thirds of the esophagus and most of malignant melanomas are located over this area. 8 Endoscopic biopsy yields diag--nostic specimens only 50% of the time. 4 The histopatho--logical diagnosis is not established until after resection is performed.
Despite our growing understanding of this malig--nant disease, the prognosis of esophageal melanoma re--mains poor, with a 5-year survival rate after surgery of 4.2%. 8 This is most likely because of the advanced state of these tumors at the time of diagnosis, with metasta--ses commonly seen. The common sites of metastases are the liver (31%), the mediastinum and mediastinal lymph nodes (29%), the lung (17.7%) and the brain (13.2%). 3 For lymph node metastasis, FDG PET detected 100% of metastases ≥10 mm, 83% of metastases 6-10 mm, and 23% of metastases <5 mm. Moreover, FDG PET has high sensitivity (≥93%) only for metastases with more than 50% lymph node involvement or with capsular in--filtration. 2 The choice of treatment for this condition is mainly dependent on the patient' s functional status and the presence and extent of metastatic disease at the time of diagnosis. 10 Surgical resection with total esophagec--tomy remains the main component of management, even in cases of recurrence. Although radiotherapy and chemotherapy have not proven to be beneficial, they play a palliative role after surgical consideration. 11 Our case demonstrates the importance of PET, which is helpful in finding metastasis to the cervical node. In our opin--ion, PET should be used in those who are diagnosed with primary malignant melanoma of the esophagus that may increase the accuracy of staging.
